1. Altman DG, Lausen B, Sauerbrei W (1994) Danger of using ‘optimal’ cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 86(11): 829–835
2. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, von Jürgenson S, Wandert T, Patzelt T, Reitz M . (2001) IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal-cell carcinoma: long-term results of a controlled randomised clinical trial. Br J Cancer 85(8): 1130–1136
3. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornaia P, Loening SA, Roigas J, Müller SC, Westerhausen H, Helbig W, Bodenstein H, Pomer S, Metzner B, Rebmann U, Hofstetter A, Oberneder R, Siebels TI, Wandert T, Patzelt T, Reitz M, DGCIN-Group (2002) 13-CIS-retinoic acid, IFN-alpha2a, IL-2 and chemotherapy in advanced renalcell carcinoma: results of a prospectively randomized trial of The German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (submitted).
4. Atzpodien J, Korfer A, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I, Hadam M . (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet; 335: 1509–1512
5. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer: 72(3): 424–430